Eterna Therapeutics
ERNA
47 hedge funds and large institutions have $52.1M invested in Eterna Therapeutics in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 4 reducing their positions, and 8 closing their positions.
350% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 4
105% more call options, than puts
Call options by funds: $638K | Put options by funds: $311K
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
10% more capital invested
Capital invested by funds: $47.3M → $52.1M (+$4.74M)
7% more funds holding
Funds holding: 44 → 47 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPWM
Cypress Point Wealth Management
Dallas,
Texas
|
+$10.3M |
| 2 |
IC
Inverness Counsel
New York
|
+$8.65M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.55M |
| 4 |
JP Morgan Chase
New York
|
+$4.19M |
| 5 |
Morgan Stanley
New York
|
+$3.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$1.22M |
| 2 |
Voloridge Investment Management
Jupiter,
Florida
|
-$453K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$191K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$163K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$110K |
ERNA Hedge Fund Activity: Q4 2021 in Review
47 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q4 2021, worth a combined $52.1M — up 10% from $47.3M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ERNA positions and 8 closed out — a net gain of 3 holders — while 18 added to existing stakes and 4 trimmed.
The largest buyer was Cypress Point Wealth Management, adding an estimated $10.3M. The largest seller was Eagle Asset Management, exiting entirely with an estimated $1.22M sold.
- 47 institutional investors held Eterna Therapeutics (ERNA) as of Q4 2021, up from 44 in Q3 2021.
- Funds reported $52.1M of Eterna Therapeutics stock for Q4 2021, up 10% quarter-over-quarter.
- 11 funds opened new Eterna Therapeutics positions in Q4 2021 and 8 closed out, a net change of +3 holders.
- The largest Eterna Therapeutics buyer in Q4 2021 was Cypress Point Wealth Management, an estimated $10.3M added.
- The largest Eterna Therapeutics seller in Q4 2021 was Eagle Asset Management, an estimated $1.22M sold.
Based on aggregated 13F filings for Q4 2021.